Skip to main content
. 2019 Feb 4;9(2):17. doi: 10.1038/s41408-019-0178-8

Fig. 4. Presence of plasma cells (CD45dim/CD38++/CD138+) at baseline vs. post-treatment.

Fig. 4

a Gating strategy. b Representative patient with plasma cell depletion following dosing with DFRF4539A. c Representative patient without plasma cell depletion following dosing with DFRF4539A